Active startups include companies in which WARF currently holds equity. Successful exits include companies in which WARF invested, which were then either acquired by major corporations or went public.
Interested in learning more about one of these companies? Contact [email protected]
Artificial intelligence to evaluate treatment response in complex diseases
Device to improve atrial arrhythmia diagnosis
Human neural cells for discovery and therapy
The world's lightest, most powerful non-rare earth electric motors and non-contact power transfer devices
Innovative cancer drug development
Conversational intelligence platform
Developing an imaging platform technology to assess how live tumor cells respond to cancer therapies
Innovative surgical navigation tool for tumor excision
Galilei BioSciences Inc.
Developing sirtuin drugs
Screening and determination of the aggressiveness of prostate cancer
Gene therapy for pediatric patients with a retinal blinding disease
Multifunctional polymeric nanofilms technology that provides cutting edge solutions in wound healing
Contract research organization providing analytical research services for drug discovery
Building an ecosystem of quantum technologies & commercial products, driving the industry towards tomorrow
Regenerative therapy company developing technology that acts as pre-formed, anatomically-inspired, implantable tissue pathways to directly replace lost connections due to brain degeneration or injury
Non-invasive patented platform technology used to monitor health status by measuring and analyzing isotopic biomarkers through exhaled breath
Stand-up CT scanner and radiotherapy system that reduces the cost of radiotherapy and improves cancer patient outcomes through upright positioning
Personalized cancer treatments to patients
DNA vaccines intended to treat prostate cancer at crucial stages in the disease
Medical device for precise fluorescence image-guided surgery
Globally accessible, non-invasive and precise diagnostic test for ovarian cancer
Produces a renewable, sustainable and cost-effective alternative to an oil-based chemical (1,5-pentanediol) found in everyday materials including paint, nylon and other plastics
Gathers alternative stock data from across the internet and aggregates it in an easy-to-use web dashboard and mobile app designed for non-professional investors.
Realta is developing industrial heat and power from fusion.
Metabolomic technologies to understand cell biology in both health and disease
First in class ophthalmology drug platform targeting the body’s extracellular matrix.
Harmonizes the veterinary referral management process, making it easy to request, send, and review veterinary medical records.
Ubicept revolutionizes how machines perceive the world by combining next-generation image sensors with advanced computer vision algorithms.
Seeking to discover and develop a bispecific antibody therapuetic for the treatment of neuroblastoma
Reliable, rugged and efficient laser and electro-optical systems for defense and security applications
Fully functioning human cells in industrial quantities IPO preceded acquisition Acquired by Fujifilm in 2015
Gala Design Inc.
Pharmaceuticals and biotech company focused on pharmaceutical preparations business
Fast, minimally invasive and highly effective soft tissue ablation system Acquired by Ethicon in 2016
DNA microarrays, consumables and instruments Acquired by Roche in 2007
Organosilicon compounds for energy storage devices, especially electrolytes for lithium-ion batteries
Skin regeneration and repair products for therapeutic use Acquired by Mallinckrodt Pharmaceuticals in 2016
Online studying platform for high school and college students
Molecular diagnostics for DNA and RNA analysis applications Acquired by Hologic in 2008
Skeletal reconstruction and bone regeneration technology
Precise cancer treatment system IPO preceded acquisition Acquired by Accuray in 2011
Platform that converts soluble biomass-derived sugars into gasoline, diesel and more Acquired by TESORO in 2016